Molecular Biology of Neurodegenerative Diseases: Visions for the Future - Part B
- 1st Edition, Volume 177 - January 14, 2021
- Imprint: Academic Press
- Editor: David B. Teplow
- Language: English
- Hardback ISBN:9 7 8 - 0 - 1 2 - 8 2 4 1 4 3 - 1
- eBook ISBN:9 7 8 - 0 - 1 2 - 8 2 4 1 4 4 - 8
Molecular Biology of Neurodegenerative Diseases: Visions for the Future, Part B, Volume 177 in the Progress in Molecular Biology and Translational Science series, provides the… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteMolecular Biology of Neurodegenerative Diseases: Visions for the Future, Part B, Volume 177 in the Progress in Molecular Biology and Translational Science series, provides the most topical, informative and exciting monographs available on a wide variety of research topics. The series includes in-depth knowledge on the molecular biological aspects of organismal physiology, with this release including chapters on Alzheimer's disease, Prion-like propagation of alpha-synuclein, What - if anything - can we learn about neurodegenerative diseases from yeast?, Mitochondrial rejuvenation and replacement as a novel strategy for treatment of age-related neurodegenerative diseases, and more.
- Includes comprehensive coverage of molecular biology
- Presents ample use of tables, diagrams, schemata and color figures to enhance the reader's ability to rapidly grasp the information provided
- Contains contributions from renowned experts in the field
Scientists working actively in a field, including those at levels ranging from graduate student to senior investigator. New investigators to a field who wish to familiarize themselves with the latest work
- Cover image
- Title page
- Table of Contents
- Copyright
- Contributors
- Preface
- Chapter One: Relevance of transgenic mouse models for Alzheimer's disease
- Abstract
- Highlights
- 1: Introduction
- 2: AD is complex, therefore realistic research expectations are important
- 3: Why do we need AD animal models?
- 4: Modeling risk factors
- 5: Study designs for therapeutic interventions
- 6: How do we want our work to be perceived both within the field and by the public?
- Acknowledgments
- Chapter Two: Mitochondrial transplant to replenish damaged mitochondria: A novel therapeutic strategy for neurodegenerative diseases?
- Abstract
- 1: Introduction
- 2: Mitochondrial dysfunctions in neurodegenerative diseases
- 3: Cell-to-cell mitochondria transfer
- 4: Treatment intervention with isolated mitochondria in cell culture
- 5: Treatment intervention with isolated mitochondria in vivo in animal models
- 6: Treating neurodegenerative diseases with isolated mitochondria?
- 7: Immune response to cell free mitochondria
- 8: Conclusions and perspectives
- Chapter Three: Activity-dependent neuroprotective protein (ADNP)-end-binding protein (EB) interactions regulate microtubule dynamics toward protection against tauopathy
- Abstract
- 1: Introduction
- 2: Aims and working hypotheses of the current review
- 3: In depth coverage of publications answering the questions posed above
- 4: Methods and results
- 5: Discussion
- 6: Future studies
- Chapter Four: Applying available knowledge and resources to alleviate familial and sporadic neurodegenerative disorders
- Abstract
- 1: An ounce of prevention is worth a ton of cure
- 2: Do we or do we not want to prevent familial neurodegenerative disorders?
- 3: Many pathways to and from sporadic neurodegenerative disorders
- 4: Prevention and risk reduction prescriptions
- 5: Pharmacological interventions: Perform many small clinical trials to identify interventions with a major impact on LONDD
- 6: The problem of disease-promoting “forces” in a profit-driven society
- 7: Concluding remarks
- Chapter Five: The cellular machinery of post-endocytic APP trafficking in Alzheimer's disease: A future target for therapeutic intervention?
- Abstract
- 1: Introduction
- 2: The post-GWAS era, Alzheimer's disease, and endosomal trafficking
- 3: Endosomal pathology precedes extracellular Aβ pathology in AD
- 4: The endosomal axis in AD: A future target for therapeutic intervention?
- 5: Conclusion
- Chapter Six: The search for novel targets in Alzheimer's disease—The 90s redux
- Abstract
- 1: Different hypotheses of AD pathogenesis as basis for a therapy
- 2: The amyloid cascade hypothesis turns 30
- 3: Anti-amyloid drugs as disease modifiers
- 4: Old paths to follow—Revival of the 90s—And new avenues on the horizon
- Acknowledgments
- Chapter Seven: Adult hippocampal neurogenesis in Alzheimer's disease
- Abstract
- 1: Introduction
- 2: Adult hippocampal neurogenesis in learning and memory
- 3: Deficits in neurogenesis in Alzheimer's disease mouse models
- 4: Adult hippocampal neurogenesis in primates
- 5: Adult hippocampal neurogenesis in aging humans and AD patients
- 6: Modulation of neurogenesis: A potential therapeutic approach for the treatment of AD
- 7: Remaining questions and concluding remarks
- Chapter Eight: Early detection and personalized medicine: Future strategies against Alzheimer's disease
- Abstract
- 1: Introduction
- 2: AD: General background
- 3: Genetic heterogeneity of AD
- 4: AD biomarkers
- 5: Current drug pipeline for AD
- 6: Personalized medicine for AD
- 7: Conclusion
- Chapter Nine: Inflammation and Parkinson's disease pathogenesis: Mechanisms and therapeutic insight
- Abstract
- 1: Introduction
- 2: Parkinson's disease as an oligomeropathy
- 3: Role of inflammation
- 4: Therapeutic approach: Possible role of doxycycline
- 5: Conclusions
- Index
- Edition: 1
- Volume: 177
- Published: January 14, 2021
- No. of pages (Hardback): 220
- No. of pages (eBook): 220
- Imprint: Academic Press
- Language: English
- Hardback ISBN: 9780128241431
- eBook ISBN: 9780128241448
DT
David B. Teplow
David B. Teplow, Ph.D., is a Professor of Neurology, Emeritus, at UCLA and an internationally recognized leader in efforts to understand and treat Alzheimer's disease. Dr. Teplow's group has used a multi-disciplinary approach to determine how neurotoxic peptides, such as the amyloid β-protein (Alzheimer's disease) and α-synuclein (Parkinson’s disease), form neurotoxic structures that kill neurons and to develop the means to block these processes. Dr. Teplow received undergraduate training at UC Berkeley; a Ph.D. from the University of Washington; and was a postdoctoral scholar at Caltech. Before coming to UCLA, Dr. Teplow was a faculty member in the Department of Neurology, Harvard Medical School. Dr. Teplow has published >250 peer-reviewed articles, books and book chapters, and commentaries, in addition to serving on numerous national and international scientific advisory boards. Dr. Teplow was a founding editor of the Journal of Molecular Neuroscience and Current Chemical Biology, He is Co-Editor-in-Chief of the Elsevier serial Progress in Molecular Biology and Translational Science and is Associate Editor-in-Chief of the American Journal of Neurodegenerative Disease.
Affiliations and expertise
Department of Neurology, David Geffen School of Medicine, UCLA, Los Angeles, CA, USARead Molecular Biology of Neurodegenerative Diseases: Visions for the Future - Part B on ScienceDirect